Genmab A/S (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages

Genmab A/S (NASDAQ:GMAB) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $45.20.

A number of equities research analysts recently issued reports on GMAB shares. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Wednesday, October 16th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Morgan Stanley reissued an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Truist Financial lowered their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th.

Genmab A/S Price Performance

Shares of GMAB opened at $20.65 on Monday. The firm has a 50-day simple moving average of $23.16 and a two-hundred day simple moving average of $25.86. Genmab A/S has a 1-year low of $20.34 and a 1-year high of $32.88. The stock has a market cap of $13.67 billion, a PE ratio of 20.05, a P/E/G ratio of 0.64 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period last year, the company earned $0.47 earnings per share. As a group, sell-side analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. raised its position in Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after purchasing an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in Genmab A/S by 123.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock valued at $81,000 after acquiring an additional 1,787 shares during the period. Blue Trust Inc. lifted its stake in shares of Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after buying an additional 3,880 shares in the last quarter. Headlands Technologies LLC boosted its stake in Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after purchasing an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. grew its holdings in Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after buying an additional 478 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.